---
schema_version: "secwatch.filing_event.v1"
accession: "0001759138-26-000024"
form_type: "8-K"
ticker: "CABA"
cik: "0001759138"
company_name: "Cabaletta Bio, Inc."
filed_at: "2026-05-14T11:02:18+00:00"
generated_at: "2026-05-14T11:08:09.991518+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cabaletta Bio presents preconditioning-free clinical data and automated manufacturing data for rese-cel at ASGCT 2026

## Summary
- Two of four pemphigus vulgaris patients at lowest PC-free dose maintained drug-free responses through 6 months.
- No dose-limiting toxicities or neurotoxicity; one patient had grade 1 cytokine release syndrome.
- First two autoimmune patients dosed with rese-cel manufactured on Cell Shuttle met all release specs with similar PK/PD.
- Higher-dose PC-free data expected 2H26; initial SLE data at lowest dose expected 1H26 at EULAR 2026 Congress.

## SEC filing metadata
- accession: 0001759138-26-000024
- form_type: 8-K
- ticker: CABA
- cik: 0001759138
- company_name: Cabaletta Bio, Inc.
- filed_at: 2026-05-14T11:02:18+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759138/000175913826000024/0001759138-26-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759138/000175913826000024/caba-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001759138-26-000024
- JSON: https://secwatch.observer/filing/0001759138-26-000024.json
- Plain text: https://secwatch.observer/filing/0001759138-26-000024.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.